Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Documenti analoghi

• Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study
  di: Maspero, J, et al.
  Pubblicazione: (2018)
• A randomized, controlled phase 3 study, Liberty Asthma Quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
  di: Castro, M, et al.
  Pubblicazione: (2018)
• Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
  di: Pavord, I, et al.
  Pubblicazione: (2018)
• Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST
  di: Wenzel, SE, et al.
  Pubblicazione: (2018)
• Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
  di: Mario Castro, et al.
  Pubblicazione: (2020-01-01)